Specialized Research

SS-31

Also known as: Elamipretide, Bendavia

Molecular Identifiers

Molecular Formula

C32H49N9O5

PubChem CID

11764719

Overview

Mitochondria-targeted peptide with cardioprotective properties. Selectively binds to cardiolipin in the inner mitochondrial membrane.

Extended notation: D-Arg-Dmt-Lys-Phe-NH₂

Contains D-amino acids and modified amino acids

Half-life

~4-6 hours

Administration Route

Subcutaneous or intravenous

Category

Specialized Research

Mechanism of Action

  • Selective binding to mitochondrial cardiolipin
  • Stabilization of the electron transport chain
  • Reduction of reactive oxygen species (ROS)
  • Cardioprotection and neuroprotection

Dosage Protocol

Data compiled from the literature. This does not constitute medical advice.

Parameter Value
Dose Variable dosage per research
Frequency Per protocol
Timing Per research design
Duration Per specific study

Reported Side Effects

Adverse effects described in the literature. Severity and frequency vary between individuals.

  • Injection site pain
  • Mild headache
  • Dizziness (rare)

Presentations & Preparation

Vials of SS-31 found in the research market:

5 mg10 mg15 mg20 mg30 mg50 mg

Reconstitution

  • Diluent: Bacteriostatic water
  • Volume: Per protocol
  • Follow specific study protocol
  • Slowly inject the diluent against the vial wall
  • Gently swirl

Storage

  • Lyophilized: -20°C
  • Reconstituted: Refrigerated 2-8°C (use promptly)
  • Protect from direct light
  • Limited stability
Reconstitution Calculator

Scientific Studies

Published studies on SS-31.

2018 · Neurology

Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy

Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH
2019 · Free Radic Biol Med

Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice

Campbell MD, Duan J, Samuelson AT, Gaffrey MJ, Merrihew GE, Egertson JD, Wang L, Bammler TK, Moore RJ, White CC, Kavanagh TJ, Voss JG, Szeto HH, Rabinovitch PS, MacCoss MJ, Qian WJ, Marcinek DJ

Related Peptides

Aviptadil

50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol

B7-33

100-500 mcg per injection (subcutaneous) · Once daily

Bronchogen

5-10 mg per day via subcutaneous injection · Once daily

Cardiogen

5-10 mg per day subcutaneously · Once daily

Chonluten

5-10 mg per day subcutaneously · Once daily

Crystagen

5-10 mg per day via subcutaneous injection · Once daily